JY BioMed is advancing an umbilical cord-derived mesenchymal stem cell (UC-MSC) platform designed to leverage the regenerative, immunomodulatory, and neuro-supportive properties of MSCs. Our UC-MSC program is currently undergoing Phase 1 clinical evaluation in Taiwan to explore applications related to tissue repair, immune system modulation, and neurological health.

​

In parallel, we are developing UC-MSC-derived exosome platforms as next-generation, cell-free therapeutic candidates. Exosomes secreted by MSCs carry a rich cargo of bioactive molecules that may influence tissue regeneration, inflammatory pathways, and neuroprotective mechanisms.

​

Our development strategy focuses on scalable cell and exosome manufacturing, rigorous quality standards, and alignment with international regulatory frameworks to support future clinical advancement.